A $3 billion China investment targets localized oral solid-dose manufacturing and supply-chain redundancy to support ...

Data provided by BackOps indicates significant performance gains for early adopters across various industries, including retail, grocery, and manufacturing. The platform reportedly accelerates ...

In today’s Pharma Pulse, the FDA launched a unified monitoring system to enable real-time adverse event reporting, and direct-to-employer drug purchasing models are emerging as companies look to ...

In a recent interview, Jay Bregman, founder and CEO of Andel, discussed his company's newly launched direct-to-employer medication platform, which is designed to reduce prescription drug costs by ...

The FDA launched AEMS, a unified platform that replaces fragmented legacy databases to enable real-time adverse event reporting.

Section 804 creates a legal pathway for states and tribes to import certain Canadian prescription drugs, contingent on demonstrable consumer savings and adherence to FDA public health safeguards. Cost ...

In today's Pharma Pulse, the NCPA warns of a severe cash flow crisis for independent pharmacies under the Medicare Drug Price ...

In today's Pharma Pulse, Ipsen voluntarily withdraws tazemetostat due to safety signals, while the FDA approves deucravacitinib for active psoriatic arthritis.

Agreement enables Hims & Hers users to access branded Ozempic 0.5–2 mg and Wegovy injectable 0.25–2.4 mg plus oral strengths 1.5–25 mg. Hims & Hers will cease marketing compounded GLP-1 products and ...

Demographic, regulatory, and geopolitical pressures compound SM-to-CGT portfolio diversification, adding short lifecycles, ultra-cold logistics, patient-window ...

In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while ...

A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity ...